-
Personalised cancer vaccine safe and potentially beneficial to patients
europeanpharmaceuticalreview
April 12, 2021
Mount Sinai researchers reveal that, in a Phase I trial, their personalised cancer vaccines targeting cancer neoantigens showed some early signs of potential benefit.
-
Immunotherapy vaccine shows promise in prostate cancer patients
europeanpharmaceuticalreview
March 31, 2021
The multi-targeted hAd5 immunotherapy vaccine was found to be safe and showed initial signs of efficacy in patients with advanced metastatic castration-resistant prostate cancer.
-
GeoVax Expands Intellectual Property Portfolio
americanpharmaceuticalreview
March 09, 2021
GeoVax Labs announced the filing of two additional patent applications important to the Company’s key focus on vaccines against SARS-CoV-2 (COVID-19) and cancer immunotherapies.
-
Radiotherapy responses may be improved with targeted immunotherapy, study suggests
pharmatimes
March 08, 2021
A new study suggests that targeted immunotherapy could make cancers that are resistant to radiotherapy more responsive to treatment.
-
Onward Therapeutics Makes a Strategic Investment in EMERCell for Their NK Cell Technology for Immunotherapy
prnasia
February 22, 2021
Onward Therapeutics SA (Onward) announced today the execution of a strategic investment in EMERCell SAS, Montpellier, France, a company that has developed a platform technology to produce off-the-shelf natural killer (NK) cells.
-
FibroGenesis Reports Positive Data in Pancreatic, Breast Cancer Using Fibroblast-Based Immunotherapy
americanpharmaceuticalreview
February 20, 2021
FibroGenesis announced new data supporting utilizing its fibroblast-based immunotherapy for successful inhibition and induction of regression in preclinical models of breast cancer and pancreatic cancer.
-
AstraZeneca and UCL to collaborate on two immuno-oncology projects
pharmatimes
February 04, 2021
British drugmaker and researchers from the UCL Division of Infection & Immunity will collaborate on two projects which will aim to contribute to the development of new cancer treatments.
-
Gilead, Gritstone Enter Vax Platform Pact for HIV Cure
contractpharma
February 02, 2021
Aims to develop HIV-specific vaccine using Gritstone’s prime-boost vaccine platform with antigens developed by Gilead.
-
ImmunityBio and NantKwest announce merger
expresspharma
December 22, 2020
Merged entity brings together 11 Phase II / III clinical trials across oncology and infectious disease that use combined immunotherapy platforms.
-
Samsung Biologics partners with BioEleven for cancer immunotherapy development and manufacturing
prnasia
October 21, 2020
Samsung Biologics has entered into a partnership agreement with BioEleven to develop and manufacture BN-101A, a third-generation immunotherapy to treat cancer.